Pfizer Inc.

PFE · NYSE · ·

下次财报：2026年11月3日 · 开盘前

US$28.730.0%9月29日收盘

1M: +2.8%
6M: +7.0%
1Y: +20.7%
5Y: -14.1%

Pfizer develops, makes and sells prescription medicines and vaccines, and earns additional fees and royalties from manufacturing and commercial partnerships.

Pfizer Inc.（PFE）股票——这是一门好生意吗？ — InspectStocks

Pfizer Inc.

PFE · NYSE · ·

下次财报：2026年11月3日 · 开盘前

US$28.730.0%9月29日收盘

1M: +2.8%
6M: +7.0%
1Y: +20.7%
5Y: -14.1%

对比

Pfizer develops, makes and sells prescription medicines and vaccines, and earns additional fees and royalties from manufacturing and commercial partnerships.

怎么赚钱

Sales of its medicines and vaccines95%
Royalties3%
Contract manufacturing and drug ingredients2%
Research and development services0%

各项收入占比是对year ended December 31, 2025, high confidence的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.

再显示 3 项

Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.

谁在买4

Wholesalers, which buy prescription medicines for resale to pharmacies, hospitals and other providers.
Retailers, pharmacies, hospitals and clinics, which buy medicines directly for patients or for use in care.
Government agencies and health institutions, which buy vaccines and medicines through contracts or purchasing programs.
Insurers and pharmacy benefit managers, which negotiate rebates and decide which medicines are covered or preferred on their drug lists.

靠什么支撑，什么会击垮它

业务依赖什么

1Revenue depends on continued sales of major medicines and vaccines; generic competition after patent or regulatory exclusivity ends can reduce sales.
2Some important products rely on partnerships: Pfizer shares profits from Comirnaty with BioNTech and from Eliquis with Bristol Myers Squibb, among other collaborations.
3Sales depend on wholesalers and other distribution channels, and on insurers and pharmacy benefit managers covering products and setting their place on medicine lists.
4Pfizer buys raw materials from suppliers worldwide and relies on manufacturing sites and supply chains to make and deliver products.

可能出什么问题

1When patent protection or regulatory exclusivity ends, generic or biosimilar manufacturers can sell lower-priced alternatives. Pfizer says competition can quickly reduce sales of affected products.
2Government price-setting, required rebates and insurer demands can lower the prices Pfizer receives or limit access to its medicines. The Medicare price-negotiation program now sets a price Pfizer must offer for Eliquis.
3Drug development and regulatory approval can fail or change. Pfizer reported that a late-stage study of its investigational cancer medicine sigvotatug vedotin did not meet its main survival goal, and that it withdrew Oxbryta from the United States market after reviewing clinical and registry data.

完整财务报表 →

与同行业相比处在什么位置

三项评分，每一项都是相对我们在Drug Manufacturers General覆盖的 21 家公司的百分位。刻意分开而不揉成一个总分：便宜、上涨和经营得好是三件不同的事，一个数字会把它们是哪一件藏起来。

动量

42在同行业中满分 100

处于同行业中游

截至一个月前的 12 个月20.8%

截至一个月前的 6 个月4.6%

最近一个月被刻意剔除：回报往往在 7 到 12 个月内延续，而最新的一个月往往反转。这描述的是股价已经走过的路，不说明它接下来会怎么走。

估值

63在同行业中满分 100

高于行业内多数公司

每单位价格对应的利润2.65%

每单位价格对应的现金6.71%

每单位价格对应的营收38.90%

每单位价格对应的资产52.81%

整个企业对应的经营利润—

这些是收益率，所以数值越高越便宜——亏损的公司会排在最后，而不是被剔除。便宜不等于好：高收益率往往意味着股价是有原因才跌下来的。由 5 项指标中的 4 项混合而成。

资本配置

2/3大体克制

3 项检验未披露

资本回报率—

股东回报率0.00%

股本数量，3 年-0.6%

净债务 / EBITDA—

内部人，12 个月—

管理层怎么使用这笔钱——只按财报能回答的部分计分，绝不按占总数的比例计分。

六项资本配置检验

投入资金的回报披露不足，无法计算
债务与盈利之比没有可比的盈利用来衡量债务
回馈给股东的现金几乎全部留存
三年间的股本数量三年间股本数量减少 0.6%
现金流对派付的覆盖自由现金流覆盖了派付的部分
内部人在公开市场的买入没有内部人在公开市场交易的记录

这是对该公司在同行中所处位置的描述，不是投资建议。评分更新于 2026年9月30日。

关于Pfizer Inc.

Pfizer discovers, tests, manufactures, markets and sells medicines and vaccines around the world. Its products address conditions including cancer, heart and blood-vessel diseases, migraine, infections, immune disorders and rare diseases. It also makes medicines and drug ingredients for other companies and is winding down a research-services business for biotechnology companies.

总部: New York City, New York
成立于: 1849 (company founded, high confidence)
员工人数: 75,000 (December 31, 2025, high confidence)
上市于: NYSE
财年结束: December 31

基于 Pfizer Inc. 自己向 SEC 提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。

怎么赚钱

Sales of its medicines and vaccines95%
Royalties3%
Contract manufacturing and drug ingredients2%
Research and development services0%

各项收入占比是对year ended December 31, 2025, high confidence的估算，并非来自已提交报告的数字。

竞争对手

卖什么6

Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.

再显示 3 项

Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.

谁在买4

Wholesalers, which buy prescription medicines for resale to pharmacies, hospitals and other providers.
Retailers, pharmacies, hospitals and clinics, which buy medicines directly for patients or for use in care.
Government agencies and health institutions, which buy vaccines and medicines through contracts or purchasing programs.
Insurers and pharmacy benefit managers, which negotiate rebates and decide which medicines are covered or preferred on their drug lists.

靠什么支撑，什么会击垮它

业务依赖什么

1Revenue depends on continued sales of major medicines and vaccines; generic competition after patent or regulatory exclusivity ends can reduce sales.
2Some important products rely on partnerships: Pfizer shares profits from Comirnaty with BioNTech and from Eliquis with Bristol Myers Squibb, among other collaborations.
3Sales depend on wholesalers and other distribution channels, and on insurers and pharmacy benefit managers covering products and setting their place on medicine lists.
4Pfizer buys raw materials from suppliers worldwide and relies on manufacturing sites and supply chains to make and deliver products.

可能出什么问题

1When patent protection or regulatory exclusivity ends, generic or biosimilar manufacturers can sell lower-priced alternatives. Pfizer says competition can quickly reduce sales of affected products.
2Government price-setting, required rebates and insurer demands can lower the prices Pfizer receives or limit access to its medicines. The Medicare price-negotiation program now sets a price Pfizer must offer for Eliquis.
3Drug development and regulatory approval can fail or change. Pfizer reported that a late-stage study of its investigational cancer medicine sigvotatug vedotin did not meet its main survival goal, and that it withdrew Oxbryta from the United States market after reviewing clinical and registry data.

完整财务报表 →

与同行业相比处在什么位置

动量

42在同行业中满分 100

处于同行业中游

截至一个月前的 12 个月20.8%

截至一个月前的 6 个月4.6%

最近一个月被刻意剔除：回报往往在 7 到 12 个月内延续，而最新的一个月往往反转。这描述的是股价已经走过的路，不说明它接下来会怎么走。

估值

63在同行业中满分 100

高于行业内多数公司

每单位价格对应的利润2.65%

每单位价格对应的现金6.71%

每单位价格对应的营收38.90%

每单位价格对应的资产52.81%

整个企业对应的经营利润—

资本配置

2/3大体克制

3 项检验未披露

资本回报率—

股东回报率0.00%

股本数量，3 年-0.6%

净债务 / EBITDA—

内部人，12 个月—

管理层怎么使用这笔钱——只按财报能回答的部分计分，绝不按占总数的比例计分。

六项资本配置检验

投入资金的回报披露不足，无法计算
债务与盈利之比没有可比的盈利用来衡量债务
回馈给股东的现金几乎全部留存
三年间的股本数量三年间股本数量减少 0.6%
现金流对派付的覆盖自由现金流覆盖了派付的部分
内部人在公开市场的买入没有内部人在公开市场交易的记录

这是对该公司在同行中所处位置的描述，不是投资建议。评分更新于 2026年9月30日。

关于Pfizer Inc.

总部: New York City, New York
成立于: 1849 (company founded, high confidence)
员工人数: 75,000 (December 31, 2025, high confidence)
上市于: NYSE
财年结束: December 31

怎么赚钱

竞争对手

卖什么6

谁在买4

靠什么支撑，什么会击垮它

业务依赖什么

可能出什么问题

与同行业相比处在什么位置

关于Pfizer Inc.

怎么赚钱

竞争对手

卖什么6

谁在买4

靠什么支撑，什么会击垮它

业务依赖什么

可能出什么问题

与同行业相比处在什么位置

关于Pfizer Inc.

成长与现金——5 项中通过 4 项